FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)

Phase 2

Terminated

Conditions: Gastrointestinal Stromal Tumors

First Posted Date: 2008-10-31

Last Posted Date: 2013-04-22

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 13

Registration Number: NCT00782834

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Carcinoma Non-resectable
Metastatic Pancreatic Cancer

Interventions: Drug: gemcitabine
Drug: Erlotinib
Radiation: low dose fractionated radiotherapy

First Posted Date: 2008-09-29

Last Posted Date: 2017-03-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 27

Registration Number: NCT00761345

Locations: 🇺🇸
Karmanos Cancer Institue, Detroit, Michigan, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Reading Medical Center, West Reading, Pennsylvania, United States

The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention

Not Applicable

Completed

Conditions: Skin Cancer Prevention

Interventions: Device: UV-Detect Photos
Behavioral: Education
Behavioral: Motivational Interviewing

First Posted Date: 2008-07-03

Last Posted Date: 2018-08-31

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 197

Registration Number: NCT00709306

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

Not Applicable

Terminated

Conditions: Breast Cancer
BRCA1 Mutation

Interventions: Biological: recombinant human chorionic gonadotropin
Genetic: microarray analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: needle biopsy

First Posted Date: 2008-06-19

Last Posted Date: 2021-01-25

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 2

Registration Number: NCT00700778

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇦🇹
Universitaetsklinik fuer Frauenheilkunde, Vienna, Austria

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Placebo
Drug: Sorafenib

First Posted Date: 2008-06-10

Last Posted Date: 2015-03-06

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT00694291

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia

Not Applicable

Completed

Conditions: Precancerous Condition
Cervical Cancer

Interventions: Behavioral: Mindfulness-Based Stress Reduction
Behavioral: Healthy Lifestyles

First Posted Date: 2008-04-04

Last Posted Date: 2016-12-05

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 186

Registration Number: NCT00653146

Locations: 🇺🇸
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Metastatic Liver Cancer

Interventions: Radiation: SIRT
Drug: capecitabine

First Posted Date: 2008-01-30

Last Posted Date: 2015-09-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 34

Registration Number: NCT00604409

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: bevacizumab
Drug: Erlotinib

First Posted Date: 2007-11-06

Last Posted Date: 2022-07-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 32

Registration Number: NCT00553800

Locations: 🇺🇸
AtlantiCare Regional Medical Center, Galloway, New Jersey, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Virtua Health Cancer Program at Memorial, Mount Holly, New Jersey, United States

and more 4 locations

Physical Activity or Usual Care in Preventing Weight Gain in Women With Stage I or Stage II Breast Cancer Undergoing Chemotherapy

Phase 1

Completed

Conditions: Breast Cancer
Depression
Fatigue
Psychosocial Effects of Cancer and Its Treatment
Weight Changes

First Posted Date: 2007-07-31

Last Posted Date: 2010-02-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 380

Registration Number: NCT00509626

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants

Not Applicable

Completed

Conditions: Colorectal Cancer
Healthy, no Evidence of Disease

Interventions: Other: counseling intervention
Other: educational intervention

First Posted Date: 2007-05-24

Last Posted Date: 2016-03-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 697

Registration Number: NCT00478309

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy